arrow
M

Mathew Cherian

department of internal medicine
H指数:20
被引数:1,436

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer

三模态疗法与单纯化疗相比,在转移性炎性乳腺癌患者中与更高的总生存期相关。

2025-12-160
PRE
Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in non-metastatic HER2-negative breast cancer: a US National Cancer Database analysis

低激素受体表达对非转移性HER2阴性乳腺癌新辅助化疗反应及治疗模式的影响:一项美国国家癌症数据库分析

2025-06-090
OA
Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP

硫酸酯酶2抑制通过增加细胞外ATP使三阴性乳腺癌细胞对紫杉醇敏感

2025-03-260
OAAI
Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells

具有体外抑制活性的有效雌激素受体 β 激动剂不能抑制内分泌耐药细胞周期蛋白依赖性激酶4/6抑制剂耐药乳腺癌细胞的异种移植

2025-03-260
OAAI
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status

早期三阴性乳腺癌新辅助化疗后HER2-low状态的临床疗效分析

2024-11-010
OAAI
Clinical outcomes in early-stage TNBC according to HER2-low status
2024-05-020
PRE
Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer
2024-03-220
PRE
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
2023-12-251
OAAI
Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls

新辅助化疗在局部晚期炎性乳腺癌 (IBC) 治疗中的生存结果与匹配对照组比较

BREAST
IF7.9
2023-12-013
OAAI
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ERD/HER2L breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

lasofoxifene联合abemaciclib治疗转移性ERD/HER2L乳腺癌和先前治疗疾病进展后ESR1突变的女性的开放标签,II期,多中心研究: ELAINE 2

2023-12-0114
OA
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
2023-06-240
OAAI
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
2023-06-011
OAAI
Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial
2023-06-012
PRE
Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+and HER2low breast tumors using multiplexed immunofluorescence
2023-04-040
PRE